Endorsed resource - Lipid management national treatment algorithm and pathway

NHS England has produced an algorithm and pathway that accurately reflects recommendations in the NICE guidelines on familial hypercholesterolaemia, and cardiovascular disease as well as NICE technology appraisal guidance on ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia, alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia and evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. It also supports statements 1, 2 and 6 in the NICE quality standard on familial hypercholesterolaemia and statements 1, 2, 3, 5, 6, 7 and 8 in the NICE quality standard on cardiovascular risk assessment and lipid modification.

Disclaimer

Endorsed resources are complementary to NICE guidance and are not produced by NICE. This resource has been developed by NHS England, and is not maintained by NICE. NICE has not made any judgement about the quality and usability of the resource. In the event of any issues or errors, please contact NHS England.


This page was last updated: